AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
17min chapter
Rerun: Lars Fruergaard Jørgensen CEO of Novo Nordisk
In Good Company with Nicolai Tangen
Pharmaceutical Company's Journey in Developing Drug for Obesity
The chapter details the pharmaceutical company's century-long focus on diabetes and the development of a drug targeting the GLP1 mechanism with benefits for weight loss and glucose control. It discusses the challenges faced in drug development, ensuring appropriate patient access, educating physicians, and balancing profitability with global reach. The chapter contrasts the pharmaceutical industry's proposals for ensuring access to medical innovations in Europe with potential policy changes that could impact investment recoupment and patient access to new medicines.
00:00
Transcript
Episode notes
Get the Snipd
podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any
moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share
& Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode